Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Other Income (Expense)

Other Income (Expense) at other companies

McKesson logo
McKessonMCK
$66M+3.1%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$468K-127%
Cencora logo
CencoraCOR
$16.88M-84.7%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
-$3.9M-160%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
-$41.2M-124%
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
-$473K-115%

Segments

By segment

See full
Affordable Medicines$1.3M
AvKARE$0

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss on refinancing(3,510)
Increase in tax receivable agreement liability(2,439)(4,420)(106)(15,107)
Other income, net6531,6041,3952,122
Total other expense, net(58,779)(59,661)(120,375)(122,522)
Income before income taxes70,99051,711151,16689,197
Provision for income taxes1,37616,1013,55228,969
Net income69,61435,610147,61460,228
Less: Net income attributable to non-controlling interests(11,952)(13,193)(27,696)(25,616)

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s other income (expense)?
Amneal Pharmaceuticals, Inc. (AMRX) reported other income (expense) of -$58.78M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s other income (expense) changed year-over-year?
Amneal Pharmaceuticals, Inc.'s other income (expense) increased by 1.5% year-over-year, from -$59.66M to -$58.78M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s other income (expense)?
Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s other income (expense) has grown at a 20.4% compound annual growth rate (CAGR), from -$121.35M to -$254.89M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Amneal Pharmaceuticals, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude